HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Joren C. Madsen James S. Allan Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Madsen, J. C. Articles by Allan, J. S. Search for Related Content PubMed PubMed Citation Articles by Madsen, J. C. Articles by Allan, J. S. Related Collections Molecular biology

Ann Thorac Surg 2004;77:2247-2249
© 2004 The Society of Thoracic Surgeons

---

Key references

Immunosuppression and transplant immunology

Division of Cardiac Surgery, Transplantation Biology Research Center, and Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

^* Address reprint requests to Dr Madsen, EDR 105, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
e-mail: madsen@helix.mgh.harvard.edu

The first 300 words of the full text of this article appear below.

Clinical immunosuppression in thoracic organ transplantation

21^st century immunosuppressive agents—heart
1. Baran DA, Segura L, Kushwaha S, et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant 2001;20:59–70.

2. Reichart B, Meiser B, Vigano M, et al. European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant 2001;20:249–50.

3. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66:507–15.

4. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999;18:143–9.

5. Keogh AM, (The Sirolimus Cardiac Trial Group). Progression of graft vessel disease in cardiac allograft recipients is significantly reduced by sirolimus immunotherapy: 6 month results from a phase 2, open-label study. Am J Transplant 2002:2(suppl 3):246 [Abstract].

6. Mancini D, Vigano M, Pulpon LA, et al. 24-month results of a multicenter study of everolimus for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Am J Transplant 2003:S5;550 [Abstract].

7. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621–27.

8. Koshiba T, Van Damme B, Rutgeerts O, et al. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A. Transplantation. 2003;75:945–52.

21^st century immunosuppressive agents—lung
1. Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001;71:1772–6.

2. Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 2003;125:891–900.

3. Zuckerman A, Reichenspurner H, . . . [Full Text of this Article]